Progenics Pharmaceuticals Announces Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC

By: via Benzinga
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) an oncology company focused on the development of innovative approaches to targeting and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.